In the past decade, antitumor responses have achieved unprecedented rates of long-lasting tumor responses in patients with a variety of cancers, including HCC, which can be realized by antibodies blocking the CTLA-4 or PD-1 pathway, either alone or in combination (Ribas and Wolchok, 2018). This evidence concerns the gene PDCD1 and hepatocellular carcinoma.